Related Experiment Video
Updated: Aug 14, 2026
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis
G Grön1, I Brandenburg, A P Wunderlich
1Memory Clinic, Department of Neurology, University of Ulm, Steinhoevelstr. 1, 89075 Ulm, Germany.
Abstract:
Mild cognitive impairment (MCI) is a condition with an increased risk of developing Alzheimer's disease. Chief complaint and diagnostic criterion in subjects with mild cognitive impairment is memory failure. We hypothesized that cholinergic malfunction may underlie memory impairment in these subjects and applied a low dosage of an acetylcholinesterase inhibitor and modulator of nicotinic acetylcholine receptors, galantamine (4 mg bid), for 7 days. We used neuropsychological tests to investigate attention, cognitive flexibility, verbal and visual short-term and working memory, susceptibility to interference and episodic memory and functional magnetic resonance imaging to assess spatial navigation both prior to and after treatment. Late episodic learning and delayed recall improved on treatment as did recruitment of the hippocampal region during spatial navigation. Performance in all other neuropsychological measures remained unchanged. We show that an increase of cholinergic neurotransmission in subjects with MCI specifically improves hippocampal function and thus that a cholinergic deficit is functionally relevant in subjects with MCI. Malfunction of the cholinergic system may be tackled pharmacologically via the inhibition of acetylcholinesterase even when the impairment is slight.
Insights
This study found that galantamine improved memory and hippocampal function in individuals with mild cognitive impairment (MCI). This suggests that targeting the cholinergic system can effectively treat memory deficits in early Alzheimer's disease stages.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Mild cognitive impairment (MCI) is a precursor to Alzheimer's disease, characterized by memory deficits.
- Cholinergic system dysfunction is a potential cause of memory impairment in MCI.
- Galantamine, an acetylcholinesterase inhibitor, modulates nicotinic acetylcholine receptors.
Purpose of the Study:
- To investigate the effects of low-dose galantamine on cognitive function and hippocampal activity in MCI patients.
- To determine if cholinergic system enhancement can improve memory and spatial navigation in MCI.
- To assess the functional relevance of cholinergic deficits in mild cognitive impairment.
Main Methods:
- A 7-day treatment with low-dose galantamine (4 mg twice daily).
- Neuropsychological tests assessing attention, memory, and executive functions.
- Functional magnetic resonance imaging (fMRI) to evaluate spatial navigation and hippocampal recruitment.
Main Results:
- Significant improvements in late episodic learning and delayed recall were observed post-treatment.
- Enhanced recruitment of the hippocampal region during spatial navigation tasks.
- No significant changes in other cognitive measures, indicating specific effects.
Conclusions:
- Cholinergic neurotransmission enhancement with galantamine specifically improves hippocampal function in MCI.
- A cholinergic deficit is functionally relevant in the memory impairment associated with MCI.
- Pharmacological targeting of the cholinergic system, via acetylcholinesterase inhibition, is a viable strategy for treating even mild cognitive impairments.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:29Alzheimer Disease l: Introduction
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...